<VariationArchive VariationID="11169" VariationName="NM_000074.3(CD40LG):c.189dup (p.Val64fs)" VariationType="Duplication" Accession="VCV000011169" Version="4" RecordType="classified" NumberOfSubmissions="1" NumberOfSubmitters="1" DateLastUpdated="2024-04-06" DateCreated="2013-04-04" MostRecentSubmission="2023-11-11">
  <RecordStatus>current</RecordStatus>
  <Species>Homo sapiens</Species>
  <ClassifiedRecord>
    <SimpleAllele AlleleID="26208" VariationID="11169">
      <GeneList>
        <Gene Symbol="CD40LG" FullName="CD40 ligand" GeneID="959" HGNC_ID="HGNC:11935" Source="submitted" RelationshipType="within single gene">
          <Location>
            <CytogeneticLocation>Xq26.3</CytogeneticLocation>
            <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="136648158" stop="136660390" display_start="136648158" display_stop="136660390" Strand="+" />
            <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="135730335" stop="135742548" display_start="135730335" display_stop="135742548" Strand="+" />
          </Location>
          <OMIM>300386</OMIM>
          <Haploinsufficiency last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CD40LG">Sufficient evidence for dosage pathogenicity</Haploinsufficiency>
          <Triplosensitivity last_evaluated="2020-04-08" ClinGen="https://www.ncbi.nlm.nih.gov/projects/dbvar/ISCA/isca_gene.cgi?sym=CD40LG">No evidence available</Triplosensitivity>
        </Gene>
      </GeneList>
      <Name>NM_000074.3(CD40LG):c.189dup (p.Val64fs)</Name>
      <CanonicalSPDI>NC_000023.11:136650294:TTTT:TTTTT</CanonicalSPDI>
      <VariantType>Duplication</VariantType>
      <Location>
        <CytogeneticLocation>Xq26.3</CytogeneticLocation>
        <SequenceLocation Assembly="GRCh38" AssemblyAccessionVersion="GCF_000001405.38" forDisplay="true" AssemblyStatus="current" Chr="X" Accession="NC_000023.11" start="136650294" stop="136650295" display_start="136650294" display_stop="136650295" variantLength="1" positionVCF="136650294" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
        <SequenceLocation Assembly="GRCh37" AssemblyAccessionVersion="GCF_000001405.25" AssemblyStatus="previous" Chr="X" Accession="NC_000023.10" start="135732453" stop="135732454" display_start="135732453" display_stop="135732454" variantLength="1" positionVCF="135732453" referenceAlleleVCF="A" alternateAlleleVCF="AT" />
      </Location>
      <ProteinChange>V64fs</ProteinChange>
      <HGVSlist>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="LRG_141" sequenceAccession="LRG_141">
            <Expression>LRG_141:g.7122dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh37" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.10" sequenceAccession="NC_000023" sequenceVersion="10" change="g.135732457dup" Assembly="GRCh37">
            <Expression>NC_000023.10:g.135732457dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Assembly="GRCh38" Type="genomic, top-level">
          <NucleotideExpression sequenceAccessionVersion="NC_000023.11" sequenceAccession="NC_000023" sequenceVersion="11" change="g.136650298dup" Assembly="GRCh38">
            <Expression>NC_000023.11:g.136650298dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="genomic">
          <NucleotideExpression sequenceAccessionVersion="NG_007280.1" sequenceAccession="NG_007280" sequenceVersion="1" change="g.7122dup">
            <Expression>NG_007280.1:g.7122dup</Expression>
          </NucleotideExpression>
        </HGVS>
        <HGVS Type="coding">
          <NucleotideExpression sequenceAccessionVersion="NM_000074.3" sequenceAccession="NM_000074" sequenceVersion="3" change="c.189dup" MANESelect="true">
            <Expression>NM_000074.3:c.189dup</Expression>
          </NucleotideExpression>
          <ProteinExpression sequenceAccessionVersion="NP_000065.1" sequenceAccession="NP_000065" sequenceVersion="1" change="p.Val64fs">
            <Expression>NP_000065.1:p.Val64fs</Expression>
          </ProteinExpression>
          <MolecularConsequence ID="SO:0001589" Type="frameshift variant" DB="SO" />
        </HGVS>
      </HGVSlist>
      <XRefList>
        <XRef Type="Allelic variant" ID="300386.0013" DB="OMIM" />
        <XRef Type="rs" ID="193922134" DB="dbSNP" />
      </XRefList>
      <Comment DataSource="NCBI curation" Type="public">NCBI staff provided an HGVS expression for allelic variant 300386.0013 from the sequence reported in Figure 2 of the paper by Kraakman et al., 1995 (PubMed 7586644).</Comment>
    </SimpleAllele>
    <RCVList>
      <RCVAccession Title="NM_000074.3(CD40LG):c.189dup (p.Val64fs) AND Hyper-IgM syndrome type 1" Accession="RCV000011919" Version="20">
        <ClassifiedConditionList TraitSetID="3084">
          <ClassifiedCondition DB="MedGen" ID="C0398689">Hyper-IgM syndrome type 1</ClassifiedCondition>
        </ClassifiedConditionList>
        <RCVClassifications>
          <GermlineClassification>
            <ReviewStatus>no assertion criteria provided</ReviewStatus>
            <Description DateLastEvaluated="1995-07-01" SubmissionCount="1">Pathogenic</Description>
          </GermlineClassification>
        </RCVClassifications>
      </RCVAccession>
    </RCVList>
    <Classifications>
      <GermlineClassification DateLastEvaluated="1995-07-01" NumberOfSubmissions="1" NumberOfSubmitters="1" DateCreated="2013-04-04" MostRecentSubmission="2023-11-11">
        <ReviewStatus>no assertion criteria provided</ReviewStatus>
        <Description>Pathogenic</Description>
        <Citation Type="general">
          <ID Source="PubMed">7586644</ID>
        </Citation>
        <ConditionList>
          <TraitSet ID="3084" Type="Disease" ContributesToAggregateClassification="true">
            <Trait ID="5326" Type="Disease">
              <Name>
                <ElementValue Type="Alternate">Hyper IgM immunodeficiency, X-linked</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Immunodeficiency with hyper IgM type 1</ElementValue>
                <XRef ID="Immunodeficiency+with+hyper+IgM+type+1/3776" DB="Genetic Alliance" />
              </Name>
              <Name>
                <ElementValue Type="Preferred">Hyper-IgM syndrome type 1</ElementValue>
                <XRef ID="MONDO:0010626" DB="MONDO" />
              </Name>
              <Name>
                <ElementValue Type="Alternate">X-linked hyper-IgM syndrome</ElementValue>
              </Name>
              <Name>
                <ElementValue Type="Alternate">Hyper-IgM Immunodeficiency Syndrome, Type 1</ElementValue>
              </Name>
              <Symbol>
                <ElementValue Type="Alternate">XHIM</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HIGM</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">IHIS</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <Symbol>
                <ElementValue Type="Alternate">HIGM1</ElementValue>
                <XRef Type="MIM" ID="308230" DB="OMIM" />
              </Symbol>
              <AttributeSet>
                <Attribute Type="GARD id" integerValue="73" />
                <XRef ID="73" DB="Office of Rare Diseases" />
              </AttributeSet>
              <AttributeSet>
                <Attribute Type="public definition">X-linked hyper IgM syndrome (HIGM1), a disorder of abnormal T- and B-cell function, is characterized by low serum concentrations of IgG, IgA, and IgE with normal or elevated serum concentrations of IgM. Mitogen proliferation may be normal, but NK- and T-cell cytotoxicity can be impaired. Antigen-specific responses are usually decreased or absent. Total numbers of B cells are normal but there is a marked reduction of class-switched memory B cells. Defective oxidative burst of both neutrophils and macrophages has been reported. The range of clinical findings varies, even within the same family. More than 50% of males with HIGM1 develop symptoms by age one year, and more than 90% are symptomatic by age four years. HIGM1 usually presents in infancy with recurrent upper- and lower-respiratory tract bacterial infections, opportunistic infections including Pneumocystis jirovecii pneumonia, and recurrent or protracted diarrhea that can be infectious or noninfectious and is associated with failure to thrive. Neutropenia is common; thrombocytopenia and anemia are less commonly seen. Autoimmune and/or inflammatory disorders (such as sclerosing cholangitis) as well as increased risk for neoplasms have been reported as medical complications of this disorder. Significant neurologic complications, often the result of a CNS infection, are seen in 5%-15% of affected males. Liver disease, a serious complication of HIGM1 once observed in more than 80% of affected males by age 20 years, may be decreasing with adequate screening and treatment of Cryptosporidium infection.</Attribute>
                <XRef ID="NBK1402" DB="GeneReviews" />
              </AttributeSet>
              <Citation Type="review" Abbrev="GeneReviews">
                <ID Source="PubMed">20301576</ID>
                <ID Source="BookShelf">NBK1402</ID>
              </Citation>
              <XRef ID="101088" DB="Orphanet" />
              <XRef ID="C0398689" DB="MedGen" />
              <XRef ID="MONDO:0010626" DB="MONDO" />
              <XRef Type="MIM" ID="308230" DB="OMIM" />
            </Trait>
          </TraitSet>
        </ConditionList>
      </GermlineClassification>
    </Classifications>
    <ClinicalAssertionList>
      <ClinicalAssertion ID="32152" SubmissionDate="2013-04-04" DateLastUpdated="2023-11-11" DateCreated="2013-04-04">
        <ClinVarSubmissionID localKey="300386.0013_IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1" title="CD40LG, 1-BP INS, TTT-TTTT, FS84TER_IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1" />
        <ClinVarAccession Accession="SCV000032152" DateUpdated="2023-11-11" DateCreated="2013-04-04" Type="SCV" Version="3" SubmitterName="OMIM" OrgID="3" OrganizationCategory="resource" />
        <RecordStatus>current</RecordStatus>
        <Classification DateLastEvaluated="1995-07-01">
          <ReviewStatus>no assertion criteria provided</ReviewStatus>
          <GermlineClassification>Pathogenic</GermlineClassification>
        </Classification>
        <Assertion>variation to disease</Assertion>
        <ObservedInList>
          <ObservedIn>
            <Sample>
              <Origin>germline</Origin>
              <Species>human</Species>
              <AffectedStatus>not provided</AffectedStatus>
            </Sample>
            <Method>
              <MethodType>literature only</MethodType>
            </Method>
            <ObservedData>
              <Attribute Type="Description">Hyper-IgM syndrome-1 (HIGM1; 308230) was diagnosed on the basis of serum immunoglobulin levels in a 13-year-old boy with sclerosing cholangitis who had received a liver transplant (Kraakman et al., 1995). His brother died at 7 months of age from Pneumocystis carinii pneumonia. Kraakman et al. (1995) demonstrated that the patient had an insertional mutation of an extra T and a run of 4 T's at position 231-234 in the second exon of their cDNA, leading to a frameshift and a premature stop at nucleotide position 297. After translation, a truncated protein would result, containing the first 63 of the 261 CD40L amino acids, followed by 21 unrelated amino acids. The run of T's was flanked by an internally palindromic direct repeat sequence (TTACATGAA) at nucleotide positions 221 and 238, the presence of which may have facilitated the T insertion at position 231. Satisfactory genetic counseling was possible because testing demonstrated that, whereas the patient's mother was a carrier, his clinically normal sister was not a carrier.</Attribute>
              <Citation>
                <ID Source="PubMed">7586644</ID>
              </Citation>
              <XRef DB="OMIM" ID="308230" Type="MIM" />
            </ObservedData>
          </ObservedIn>
        </ObservedInList>
        <SimpleAllele>
          <GeneList>
            <Gene Symbol="CD40LG" />
          </GeneList>
          <Name>CD40LG, 1-BP INS, TTT-TTTT, FS84TER</Name>
          <VariantType>Variation</VariantType>
          <OtherNameList>
            <Name Type="NonHGVS">1-BP INS, TTT-TTTT, FS84TER</Name>
          </OtherNameList>
          <XRefList>
            <XRef DB="OMIM" ID="300386.0013" Type="Allelic variant" />
          </XRefList>
        </SimpleAllele>
        <TraitSet Type="Disease">
          <Trait Type="Disease">
            <Name>
              <ElementValue Type="Preferred">IMMUNODEFICIENCY WITH HYPER-IgM, TYPE 1</ElementValue>
            </Name>
          </Trait>
        </TraitSet>
      </ClinicalAssertion>
    </ClinicalAssertionList>
  </ClassifiedRecord>
</VariationArchive>

